Navigation Links
UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age

ur video EEG performed at baseline and at the end of the evaluation period with seizures identified and recorded by a central reader.

Fifty million people worldwide have epilepsy[2]. Childhood epilepsy is among the most prevalent neurological conditions. The effects of epilepsy on a child's psychological and social development are complex and cover all dimensions of a child's life and future.

Peter Verdru, Vice President, CNS Clinical Development, UCB said, 'This is the second double-blind, randomized, placebo-controlled trial of Keppra® in children, with studies in partial onset seizures now extending from infancy through adulthood.' He continued, 'This trial was designed and conducted in close collaboration with the regulatory authorities. On the basis of these positive results in younger patients with treatment resistant partial seizures we intend to file a supplementary new drug application for Keppra®'.

About Keppra® in the US[3],[4] Keppra® tablets and oral solution are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy, as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy, and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy (IGE). Keppra® tablets and oral solution are associated with the occurrence of central nervous system adverse events including somnolence and fatigue, co-ordination difficulties and behavioral abnormalities as well as hematological abnormalities. In adults experiencing partial onset seizures, the most common adverse events associated with Keppra® in combination with other antiepileptic drugs (AEDs) were somnolence, asthenia, infection and dizziness. In pediatric patients 4-16 years of age experiencing
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/22/2013)... TORONTO , May 22, 2013  Medifocus, Inc. (OTCQX: ... Mon , Chief Operating Officer, will present at the ... 2013 in New York City at ... is scheduled to begin at 4:00 p.m. EDT and will ... go to:   http://wsw.com/webcast/marcum/mfs.v/   For more information ...
(Date:5/22/2013)... 22, 2013  BD (Becton, Dickinson and Company) (NYSE: ... company, announced today the publication of its 2012 ... and it continues to focus on the Company,s shared ... the principles of shared value — creating value for ... societies — are fundamental to our strategy," said ...
(Date:5/22/2013)... Cellular Biomedicine Group (OTCQB: CBMG) today announced that ... projected enrollment required for its Phase I trial to evaluate ... Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most ... had no Severe Adverse Effect (SAE) reported. The ... with NIH under number NCT01828762 (click here to view) ...
Breaking Medicine Technology:Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 2Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 3
... 7, 2011 Stereotaxis, Inc. (NASDAQ: STXS ) ... 30, 2011.   Third Quarter 2011 ... down 38% from the year ago period.  The decrease was ... from market demand for a more efficient solution for complex ...
... CARLSBAD, Calif., Nov. 7, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ... the quarter ended September 30, 2011.  The Company finished the ... loss (NOL) of $20.0 million and $44.9 million for the ... to a pro forma NOL of $6.0 million and $23.1 ...
Cached Medicine Technology:Stereotaxis Reports Third Quarter Financial Results 2Stereotaxis Reports Third Quarter Financial Results 3Stereotaxis Reports Third Quarter Financial Results 4Stereotaxis Reports Third Quarter Financial Results 5Stereotaxis Reports Third Quarter Financial Results 6Stereotaxis Reports Third Quarter Financial Results 7Stereotaxis Reports Third Quarter Financial Results 8Isis Reports Financial Results and Highlights for Third Quarter 2011 2Isis Reports Financial Results and Highlights for Third Quarter 2011 3Isis Reports Financial Results and Highlights for Third Quarter 2011 4Isis Reports Financial Results and Highlights for Third Quarter 2011 5Isis Reports Financial Results and Highlights for Third Quarter 2011 6Isis Reports Financial Results and Highlights for Third Quarter 2011 7Isis Reports Financial Results and Highlights for Third Quarter 2011 8Isis Reports Financial Results and Highlights for Third Quarter 2011 9
(Date:5/22/2013)... (PRWEB) May 22, 2013 Synthetic ... for its Better Play & Recreation Contest, who ... of thousands of youth, people with disabilities, active ... of rescue. The general public is encouraged to ... help their favorite non-profit organization win the $50,000 ...
(Date:5/22/2013)... Hypervibe, a leader in the field ... that the company’s US division will hold a Memorial ... personnel ordering the Hypervibe Performance during the sale will ... valid military ID. Non-military customers receive 10% off. ... and integrity. These are values that have made our ...
(Date:5/22/2013)... Toronto, ON (PRWEB) May 22, 2013 ... voice, video, data and IT security solutions in ... with the launch of its newest BroadConnect hosted ... or as a hybrid combination, BroadConnect’s new Security ... more effectively leverage the Internet connection of their ...
(Date:5/22/2013)... Many people across the United States struggle with ... lose weight safely and rapidly. Unfortunately, crossing initial weight ... to continue their journey toward healthy eating and healthy ... Medical News Today offers credence to the testimony ... losing those initial pounds can prove extremely difficult. , ...
(Date:5/22/2013)... 2013 Patients with type 1 diabetes ... better glycemic control as measured by significantly lower HbA1C ... with insulin injections, according to new findings from the ... by Kantar Health . The research was presented ... Society for Pharmacoeconomics and Outcomes Research) in New Orleans. ...
Breaking Medicine News(10 mins):Health News:Public Voting Opens for Finalists in Synthetic Turf International’s Better Play & Recreation Contest 2Health News:Hypervibe Whole Body Vibration Offers First-Ever Sale This Memorial Day Weekend 2Health News:BroadConnect Telecom to Launch Enterprise-Grade Hosted Security Solutions Engineered to Meet the Demands of Real World Business 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Break the Cycle of Obesity and Weight Gain With New Education For Patients on How to Lose Weight the Healthy Way 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Break the Cycle of Obesity and Weight Gain With New Education For Patients on How to Lose Weight the Healthy Way 3Health News:Insulin Pump Therapy Provides Better Glycemic Control Among Type 1 Diabetics, According to Kantar Health Research 2Health News:Insulin Pump Therapy Provides Better Glycemic Control Among Type 1 Diabetics, According to Kantar Health Research 3
... ... Than 20 Years of Experience to IT GRC Solutions Provider , ... Farmington Hills, Mich. (PRWEB) March 31, ... (GRC) solutions, today announced the appointment of Eric Rosenberg as chief financial officer. ...
... setting, study finds , TUESDAY, March 30 (HealthDay News) ... among children in hospital intensive care units, so patients ... a new study suggests. , Researchers found that 6 ... ICU unit at the Johns Hopkins Children,s Center between ...
... , ... announced May 24th in honor of Mental Health Awareness Month , ... San Francisco (PRWEB) March 31, 2010 -- SharpBrains, ... and commercial applications, today announced the launch of the inaugural Brain Fitness Innovation Awards. The ...
... ... (Pittsburgh, Pa.) and Blount Memorial Hospital (Knoxville, Tenn.) are the first hospitals in ... enables nurses and doctors to better coordinate care. , ... Knoxville, TN (PRWEB) March 31, ...
... ... – May 30, people age 65 and older can call to determine if they qualify for ... ... but don’t worry if you don’t have the change to spare for an eye exam. ...
... ... , ... March 31, 2010 -- The Medpedia Project today announced the addition of health and medical ... hundreds of medical and health videos from sources including the CDC, the FDA, other institutes ...
Cached Medicine News:Health News:Children in Intensive Care Should Be Screened for MRSA 2Health News:SharpBrains Launches First Brain Fitness Innovation Awards to Recognize Neuroplasticity Pioneers 2Health News:SharpBrains Launches First Brain Fitness Innovation Awards to Recognize Neuroplasticity Pioneers 3Health News:New PerfectServe Clinician-to-Clinician Communications System Gives Physicians Control and Helps Hospitals Coordinate Care 2Health News:New PerfectServe Clinician-to-Clinician Communications System Gives Physicians Control and Helps Hospitals Coordinate Care 3Health News:New PerfectServe Clinician-to-Clinician Communications System Gives Physicians Control and Helps Hospitals Coordinate Care 4Health News:EyeCare America Ushers in the New Season and Springs for Eye Exams for Qualified Seniors 2Health News:EyeCare America Ushers in the New Season and Springs for Eye Exams for Qualified Seniors 3Health News:MEDPEDIA Adds Health and Medical Videos To Platform 2Health News:MEDPEDIA Adds Health and Medical Videos To Platform 3Health News:MEDPEDIA Adds Health and Medical Videos To Platform 4
... The K-ASSAY Liquid Lipid Control is intended ... a consistent test sample of known concentration ... determinations. Include K-ASSAY Liquid Lipid Control with ... of the listed constituents. The user can ...
The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
The K-ASSAY Anti-Streptolysin O Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifyi...
... The Directigen EZ Flu A+B test is ... and qualitative detection of influenza A and ... throat swabs of symptomatic patients. The Directigen ... test, such that influenza A viral antigens ...
Medicine Products: